News

1 2 3 4 6 10 15 19
NEWS

SOTIO Exercises Option for Novel Antibody-Drug Conjugate Program under Agreement with LegoChem Biosciences

  • SOT106 is an antibody-drug conjugate (ADC) targeting an attractive surface antigen expressed on multiple solid tumors.
  • Preclinical efficacy and tolerability studies of SOT106 show promising results across multiple solid tumor indications and a beneficial therapeutic index.
  • SOTIO is actively exploring additional tumor targets to expand the collaboration with LegoChem Biosciences to up to five ADC programs.

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, today announced that is has exercised its first of five exclusive, target-specific options with LegoChem Biosciences (LCB, KOSDAQ: 141080) for antibody-drug conjugate (ADC) SOT106, which is currently being evaluated in preclinical studies across a multitude of solid tumor indications. 

NEWS

SOTIO Bolsters Leadership Team with Appointment of Martin Steegmaier as Chief Scientific Officer

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced the appointment of Martin Steegmaier, Ph.D., MBA, as chief scientific officer. Martin Steegmaier brings over 20 years of experience in oncology drug discovery, drug development and business development. His extensive knowledge of the biotech industry and clinical immuno-oncology will be crucial as SOTIO continues to advance multiple assets through the clinic. He will be responsible for preclinical and translational research globally.

NEWS

SOTIO Strengthens Management Team with Appointment of Robyn Hunter as Chief Financial Officer

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announces the appointment of Robyn Hunter as chief financial officer. Ms. Hunter is an accomplished CFO who brings an extensive array of financial experience to SOTIO, including her extensive knowledge of biotech and capital markets. She joins SOTIO to oversee the long-term financing strategy.